

## ***Seminar Notice***

# ***p53-based Therapy for Cancer***

***Professor Sir David Lane, PhD FRS FRSE FMedSci***  
***Chief Scientist, A\*STAR***  
***Chairman, Chugai Pharmabody Research Pte Ltd***



Professor Sir David Lane is one of the scientists credited with the landmark discovery of cancer gene p53 in 1979. p53, called the "Guardian of the genome" is the most frequently mutated gene in human cancer as more than half of human tumours contain mutations in the gene. He was previously the Director of the Cancer Research UK Cell Transformation Research Group and Professor of Oncology at the University of Dundee in Scotland. He had also held the position of Chief Scientist with Cancer Research UK. In 1996 Sir David founded the biotechnology company Cyclacel now listed on NASDAQ.

Sir David is currently Chief Scientist of Singapore's Agency for Science, Technology and Research (A\*STAR) and also the Chairman of Chugai Pharmabody Research Pte Ltd (CPR) which he helped to attract to Singapore. CPR represents a \$400 million 10-year investment by Chugai in research located in the Synapse building at the Biopolis, Singapore. The company currently employs over 90 highly qualified researchers developing new antibody therapeutics. Sir David's A\*Star p53 laboratory is working on peptide and antibody based therapies that target the p53 pathway and on the evolution and function of tumor suppressors. Much of the work has been in collaboration with Dr Chandra Verma's team at A\*Star BII. For his efforts in cancer research, Sir David was knighted in 2000. He also received the Cancer Research UK Lifetime Achievement Award – a prize that recognises his pioneering research that led to the discovery of p53. Sir David has also been awarded a number of International Prizes including the Paul Erlich Prize, the Josef Steiner Prize and the Brupbacher Prize.

***Date: April 25, 2018***

***Time: 12:00 noon***

***Location: Robert B. Salter Auditorium (PGCRL)***

***The Hospital for Sick Children***

***686 Bay Street, Toronto, Ontario M5G 0A4***

For more information, please contact Dr. David Malkin, [david.malkin@sickkids.ca](mailto:david.malkin@sickkids.ca)